Abstract:
Influenza A virus (IAV) infection causes severe respiratory and/or intestinal illnesses in a variety of animal hosts, such as birds and mammals. The global burden of IAV infections poses major public health problems worldwide. Current influenza vaccines require annual updating and provide only partial protection. There are only two categories of drugs available, the M2 proton channel inhibitors (amantadine) and the neuraminidase inhibitors (oseltamivir). Because viruses develop resistance to the drugs readily, we urgently need novel antiviral agents. We identified a receptor tyrosine kinase anexelekto (AXL) as a cellular factor required for IAV infection. Furthermore, we showed that treatment with an antagonist polyclonal antibody against AXL completely blocked virus infection. R428, a selective small-molecule inhibitor of AXL kinase, which has been reported to block tumor spread and prolong survival in mouse models of metastatic breast cancer, also significantly inhibited influenza A virus infection at the entry stage of infection. Thus, blockage of AXL is a potential new target for developing antiviral therapy.
Fields of Application:
Anti-infulenza
Advantages when compared to the existing technologies:
New drug target and new mechanism.
Contact Person:Tung-Ying Lu +886-2-27872552 E-mail: meiguelu@gate.sinica.edu.tw
IP Status:US TW pending
